A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Introduction In proliferative diabetic retinopathy (PDR), vascular endothelial growth factor (VEGF) and connective tissue growth factor (CTGF) may cause blindness by neovascularisation followed by fibrosis of the retina. It has previously been shown that a shift in the balance between levels of CTGF and VEGF in the eye is associated with this angiofibrotic switch. This study investigated whether anti-VEGF agents induce accelerated fibrosis in patients with PDR, as predicted by this model. Methods CTGF and VEGF levels were measured by ELISA in 52 vitreous samples of PDR patients, of which 24 patients had received intravitreal bevacizumab 1 week to 3 months before vitrectomy, and were correlated with the degree of vitreoretinal fibrosis as determined clinically and intra-operatively. Results CTGF correlated positively, and VEGF correlated negatively with the degree of fibrosis. The CTGF/VEGF ratio was the strongest predictor of fibrosis. Clinically, increased fibrosis was observed after intravitreal bevacizumab. Conclusions These results confirm that the CTGF/VEGF ratio is a strong predictor of vitreoretinal fibrosis in PDR, and show that intravitreal anti-VEGF treatment causes increased fibrosis in PDR patients. These findings provide strong support for the model that the balance of CTGF and VEGF determines the angiofibrotic switch, and identify CTGF as a possible therapeutic target in the clinical management of PDR
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Paradoxically, in eyes with proliferative diabetic retinopathy treated with anti-VEGF injections, there is increased fibrosis caused by imbalances between connective tissue growth factor and VEGF.32,33”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2007) · Developments in Ophthalmology · doi:10.1159/isbn.978-3-318-01439-6 · Cited by 5,583
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Vascular endothelial growth factors and angiogenesis in eye disease
Witmer, A. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(02)00043-5 · Cited by 927
Self-citationIntravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Avery, R. L., Pearlman, J., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.064 · Cited by 799
Fong, D. S., Aiello, L. P., Ferris, F. L., & Klein, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2540 · Cited by 640
Michaelides, M., Kaines, A., Hamilton, R. D., Fraser-Bell, S., Rajendram, R., Quhill, F., Boos, C. J., Xing, W., Egan, C., Peto, T., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.03.045 · Cited by 521
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
Arevalo, J. F., Maia, M., Flynn, H. W., Saravia, M., Avery, R. L., Wu, L., Farah, M. E., Pieramici, D. J., Berrocal, M. H., & Sanchez, J. G. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.127142 · Cited by 411
Inoki, I., Shiomi, T., Hashimoto, G., Enomoto, H., Nakamura, H., Makino, K.-I., Ikeda, E., Takata, S., Kobayashi, K.-I., & Okada, Y. (2002) · The FASEB Journal · doi:10.1096/fj.01-0332fje · Cited by 372
The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy
Kuiper, E. J., Van Nieuwenhoven, F. A., de Smet, M. D., van Meurs, J. C., Tanck, M. W., Oliver, N., Klaassen, I., Van Noorden, C. J. F., Goldschmeding, R., & Schlingemann, R. O. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002675 · Cited by 241
Self-citation
Cited by
Klaassen, I., Van Noorden, C. J. F., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 722
Self-citationRisk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
“Paradoxically , in eyes with proliferative diabetic retinopathy treated with anti-VEGF injections, there is increased fibrosis caused by imbalances between connective tissue growth factor and VEGF.”
Molecular mechanisms of subretinal fibrosis in age-related macular degeneration
Ishikawa, K., Kannan, R., & Hinton, D. R. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.03.009 · Cited by 236
Diabetic retinopathy: Breaking the barrier
Eshaq, R. S., Aldalati, A. M. Z., Alexander, J. S., & Harris, N. R. (2017) · Pathophysiology · doi:10.1016/j.pathophys.2017.07.001 · Cited by 169
Cheung, N., Wong, I. Y., & Wong, T. Y. (2014) · Diabetes Care · doi:10.2337/dc13-1990 · Cited by 166
Metadata
- Authors
- Van Geest, R. J., Lesnik-Oberstein, S. Y., Tan, H. S., Mura, M., Goldschmeding, R., Van Noorden, C. J. F., Klaassen, I., & Schlingemann, R. O.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Netherlands Institute for Neuroscience (NL)
- Corresponding author
- Schlingemann, Reinier O
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2012-01-29
- Volume
- 96
- Issue
- 4
- Pages
- 587-590
- ISSN
- 0001-639X (ISSN-L)
- 0007-1161
- 1468-2079
- PMC
- PMC3308470
- OpenAlex
- W2132899855
- Cited by
- 141
- References
- 33
- Citations by year
- 2025: 5 · 2024: 9 · 2023: 11 · 2022: 10 · 2021: 9 · 2020: 11 · 2019: 8 · 2018: 16 · 2017: 17 · 2016: 10 · 2015: 9 · 2014: 14 · 2013: 7 · 2012: 5
- Type
- conference abstract
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Acta Ophthalmologica (publishedVersion)
- British Journal of Ophthalmology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Diabetes Fonds
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
- Keywords
- proliferative diabetic retinopathy, bevacizumab, vascular endothelial growth factor, connective tissue growth factor, vitreoretinal fibrosis, anti-VEGF therapy, vitreous humor, neovascularization, vitrectomy
- MeSH terms
- Bevacizumab, Diabetic Retinopathy, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Male, Middle Aged, Vitrectomy, Vitreous Body, Retinal Neovascularization, Disease Progression, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Connective Tissue Growth Factor, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. https://app.cochat.ai/papers/10.1136/bjophthalmol-2011-301005
- The paper
- Van Geest, R. J., Lesnik-Oberstein, S. Y., Tan, H. S., Mura, M., Goldschmeding, R., Van Noorden, C. J. F., Klaassen, I., & Schlingemann, R. O. (2012). A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2011-301005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.